Melanoma Surveillance in the US: Melanoma, Ultraviolet Radiation, and Socioeconomic Status

Published Online: Wednesday, September 26, 2012
Follow Pharmacy_Times:
In this podcast from the Centers for Disease Control and Prevention, Chris Johnson, from the Cancer Data Registry of Idaho, discusses the results of several studies published in a supplement to the November 2011 edition of the Journal of the American Academy of Dermatology that examined the relationship between rates of melanoma and 2 variables recorded at the county level: ultraviolet radiation and socioeconomic status.
 
To listen to the podcast, click here.
Related Articles
The FDA has granted priority review status to Amgen’s supplemental New Drug Application for its carfilzomib (Kyprolis) cancer therapy.
Teikoku Pharma USA has submitted a New Drug Application to the FDA for the product.
Cancer drug prices have increased 10% each year since 1995, even after adjusting for inflation and incremental health benefits.
Cyramza, manufactured by Eli Lilly and Company, is an angiogenesis inhibitor indicated for the treatment of patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with disease progression on or after treatment with prior fluoropyrimidine- or platinum-containing chemotherapy.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$